CR5959A - Tratamiento para la disfuncion sexual femenina - Google Patents

Tratamiento para la disfuncion sexual femenina

Info

Publication number
CR5959A
CR5959A CR5959A CR5959A CR5959A CR 5959 A CR5959 A CR 5959A CR 5959 A CR5959 A CR 5959A CR 5959 A CR5959 A CR 5959A CR 5959 A CR5959 A CR 5959A
Authority
CR
Costa Rica
Prior art keywords
apomorphine
treatment
sexual dysfunction
female sexual
clitoris
Prior art date
Application number
CR5959A
Other languages
English (en)
Inventor
El-Rashidy Ragab
Ronsen Bruce
Original Assignee
Pentech Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pentech Pharmaceuticals Inc filed Critical Pentech Pharmaceuticals Inc
Publication of CR5959A publication Critical patent/CR5959A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

LA DISFUNSION SEXUAL EN LA MUJER PUEDE SER AMINORADA, SIN EFECTOS SECUNDARIOS SUBSTANCIALES INDESEABLES POR LA ADMINISTRACION SUBLINGUAL DE DOSIS DE APOMORFINA. LA ADMINISTRACION DE APOMORFINA INCREMENTA LA ESTIMULACION DEL CLITORIS MEDIANTE EL FLUJO DE LA SANGRE INTRACAVERNOSAL Y EL FLUJO DE SANGRE EN LAS PAREDES DE LA VAGINA PARA OBTENER LA ERECCION DEL CLITORIS Y EL CONGESTIONAMIENTO VAGINAL DE LA MUJER. LA CONCENTRACION DE PLASMA DE APOMORFINA DE NO MAS DE 5.5 MANOGRAMOS POR MILILITRO ES PREFERIBLEMENTE MANTENIDA.
CR5959A 1998-01-30 1999-01-28 Tratamiento para la disfuncion sexual femenina CR5959A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/016,252 US5945117A (en) 1998-01-30 1998-01-30 Treatment of female sexual dysfunction

Publications (1)

Publication Number Publication Date
CR5959A true CR5959A (es) 1999-07-28

Family

ID=21776169

Family Applications (1)

Application Number Title Priority Date Filing Date
CR5959A CR5959A (es) 1998-01-30 1999-01-28 Tratamiento para la disfuncion sexual femenina

Country Status (34)

Country Link
US (2) US5945117A (es)
EP (1) EP1056419A4 (es)
JP (1) JP2002501875A (es)
KR (1) KR20010040477A (es)
CN (1) CN1250221C (es)
AR (1) AR017976A1 (es)
AU (1) AU752928B2 (es)
BG (1) BG64667B1 (es)
BR (1) BR9908038A (es)
CA (1) CA2322289A1 (es)
CO (1) CO4970819A1 (es)
CR (1) CR5959A (es)
DZ (1) DZ2714A1 (es)
GC (1) GC0000096A (es)
GT (1) GT199900013A (es)
HK (1) HK1040901B (es)
HN (1) HN1999000015A (es)
HU (1) HUP0101268A3 (es)
IL (2) IL137569A0 (es)
JO (1) JO2085B1 (es)
MA (1) MA26600A1 (es)
MX (1) MXPA00007447A (es)
NO (1) NO319821B1 (es)
NZ (1) NZ506597A (es)
PA (1) PA8467801A1 (es)
PE (1) PE20000240A1 (es)
PL (1) PL194350B1 (es)
SK (1) SK11362000A3 (es)
TN (1) TNSN99008A1 (es)
TR (1) TR200002220T2 (es)
TW (1) TW550069B (es)
UY (1) UY25374A1 (es)
WO (1) WO1999038467A1 (es)
ZA (1) ZA99686B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020165122A1 (en) * 1994-04-22 2002-11-07 Heaton Jeremy P. W. Method and compositions for the treatment or amelioration of female sexual dysfunction
US6395744B1 (en) * 1994-04-22 2002-05-28 Queen's University At Kingston Method and compositions for the treatment or amelioration of female sexual dysfunction
US20050065161A1 (en) * 1996-02-02 2005-03-24 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
US6472425B1 (en) 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
AU2003204720B2 (en) * 1998-05-29 2006-06-29 Tap Pharmaceutical Products Inc. Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
EP1089736A2 (en) * 1998-06-22 2001-04-11 Queen's University At Kingston Method and compositions for the treatment or amelioration of female sexual dysfunction
US20050245494A1 (en) * 1999-07-01 2005-11-03 40 J's Llc Methods to treat one or all of the defined etiologies of female sexual dysfunction
US20040254153A1 (en) * 1999-11-08 2004-12-16 Pfizer Inc Compounds for the treatment of female sexual dysfunction
BR0005797A (pt) * 2000-03-20 2001-10-16 Abbott Lab Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
US6506765B2 (en) 2000-04-07 2003-01-14 Tap Pharmaceutical Products, Inc. Apomorphine derivatives and methods for their use
AU2001261244B2 (en) * 2000-05-09 2006-08-03 Nitromed, Inc. Infrared thermography and methods of use
ATE369868T1 (de) * 2000-06-27 2007-09-15 Qualilife Pharmaceuticals Inc Zusammensetzungen und verfahren zur behandlung der weiblichen sexuellen reaktion
US7223406B2 (en) 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
WO2002007757A2 (en) 2000-07-21 2002-01-31 Lue Tom F Prevention and treatment of sexual arousal disorders
US20020065286A1 (en) * 2000-08-21 2002-05-30 Davies Michael John Treatment of wounds
JP2004513899A (ja) 2000-11-15 2004-05-13 タツプ・フアーマシユーテイカル・プロダクツ・インコーポレイテツド 抗鬱薬誘発性的機能不全のアポモルヒネによる治療
NZ525086A (en) * 2000-11-22 2006-07-28 Abbott Lab The use of selective dopamine D4 receptor agonists for treating sexual dysfunction
EP1365740A1 (en) * 2001-02-08 2003-12-03 Pharmacia Corporation Rapid-onset medicament for the treatment of sexual dysfunction
KR20050008658A (ko) * 2002-03-19 2005-01-21 마이클 홀릭 아포모르핀의 글리코시드 및 오르토에스테르 글리코시드유도체들, 유사체들 및 그것의 용도
US20030219696A1 (en) * 2002-05-23 2003-11-27 Moreland Gerald W. Method and apparatus for preventing backflow in dental saliva evacuators
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
GB0221711D0 (en) * 2002-09-19 2002-10-30 Ardana Bioscience Ltd Methods
CA2445212A1 (en) * 2002-10-10 2004-04-10 Queen's University At Kingston Treatment of sexual dysfunction
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
RU2364400C2 (ru) * 2003-04-14 2009-08-20 Вектура Лтд Фармацевтические композиции
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
US7276246B2 (en) * 2003-05-09 2007-10-02 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US7306812B2 (en) 2003-05-09 2007-12-11 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
GB0314054D0 (en) * 2003-06-17 2003-07-23 Pfizer Ltd Amide derivatives as selective serotonin re-uptake inhibitors
US20050054688A1 (en) * 2003-08-08 2005-03-10 Pfizer Inc Selective serotonin reuptake inhibitors in the treatment of disease
DE10338174A1 (de) * 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
US7291640B2 (en) * 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
AU2005238296A1 (en) * 2004-04-30 2005-11-10 Warner-Lambert Company Llc Substituted morpholine compounds for the treatment of central nervous system disorders
GB0409744D0 (en) * 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds
EP1863484A1 (en) * 2005-03-21 2007-12-12 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
ES2313626T3 (es) * 2005-03-21 2009-03-01 Pfizer Limited Derivados de triazol sustituidos como antagonistas de oxitocina.
US20080317850A1 (en) * 2005-04-08 2008-12-25 Ernest Alan Hewitt Buccal Delivery System
CA2618103A1 (en) * 2005-08-10 2007-02-15 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
US8349850B2 (en) 2006-03-28 2013-01-08 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
US7800094B2 (en) * 2007-06-11 2010-09-21 Macronix International Co., Ltd. Resistance memory with tungsten compound and manufacturing
PT2952191T (pt) 2009-06-12 2018-11-30 Sunovion Pharmaceuticals Inc Apomorfina sublingual
US20130210867A1 (en) * 2010-04-15 2013-08-15 Life Science Enhancement Corporation Methods and compositions for enhancing female sexual arousal and treating female sexual dysfunction
EP2651357B1 (en) 2010-12-16 2020-04-01 Sunovion Pharmaceuticals Inc. Sublingual films
WO2012140642A1 (en) 2011-04-10 2012-10-18 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
EP2545905A1 (en) 2011-07-11 2013-01-16 Britannia Pharmaceuticals Limited A new therapeutical composition containing apomorphine as active ingredient
EP4578461A3 (en) 2015-04-21 2025-09-03 Sumitomo Pharma America, Inc. Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
WO1993023035A2 (en) * 1992-05-18 1993-11-25 Smithkline Beecham Plc Use of indolone derivatives for the treatment of memory disorders, sexual dysfunction and parkinson's disease
US5565466A (en) * 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
CA2188385C (en) * 1994-04-22 2000-07-11 Ragab El-Rashidy Dosage forms and method for ameliorating male erectile dysfunction
US5562917A (en) * 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
US5624677A (en) * 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction

Also Published As

Publication number Publication date
CN1313742A (zh) 2001-09-19
NO20003845D0 (no) 2000-07-27
HK1040901B (zh) 2006-11-24
EP1056419A1 (en) 2000-12-06
KR20010040477A (ko) 2001-05-15
UY25374A1 (es) 1999-09-27
WO1999038467A1 (en) 1999-08-05
HUP0101268A3 (en) 2002-12-28
NO20003845L (no) 2000-09-28
GC0000096A (en) 2005-06-29
TW550069B (en) 2003-09-01
AR017976A1 (es) 2001-10-24
TNSN99008A1 (fr) 2005-11-10
SK11362000A3 (sk) 2001-02-12
JP2002501875A (ja) 2002-01-22
AU752928B2 (en) 2002-10-03
DZ2714A1 (fr) 2003-09-01
EP1056419A4 (en) 2007-05-02
BR9908038A (pt) 2002-01-02
PL194350B1 (pl) 2007-05-31
ZA99686B (en) 1999-07-28
PA8467801A1 (es) 2000-09-29
HN1999000015A (es) 1999-08-23
CA2322289A1 (en) 1999-08-05
BG64667B1 (bg) 2005-11-30
MA26600A1 (fr) 2004-12-20
BG104715A (bg) 2001-02-28
HK1040901A1 (en) 2002-06-28
CN1250221C (zh) 2006-04-12
IL137569A0 (en) 2001-07-24
GT199900013A (es) 2001-07-20
PE20000240A1 (es) 2000-03-31
US6193992B1 (en) 2001-02-27
TR200002220T2 (tr) 2000-12-21
IL137569A (en) 2006-08-01
US5945117A (en) 1999-08-31
JO2085B1 (en) 2000-05-21
CO4970819A1 (es) 2000-11-07
NZ506597A (en) 2003-07-25
NO319821B1 (no) 2005-09-19
MXPA00007447A (es) 2006-01-25
HUP0101268A2 (hu) 2001-09-28
PL342062A1 (en) 2001-05-21
AU2564499A (en) 1999-08-16

Similar Documents

Publication Publication Date Title
PA8467801A1 (es) Tratamiento de disfuncion sexual femenina
EP1253929A4 (en) USE OF RELAXIN FOR THE TREATMENT OF DISEASES CONTAINED BY VASCARIAL CONSTRUCTION
EA200001044A3 (ru) Соединения для лечения женской сексуальной дисфункции
US5891915A (en) Method for enhancing female sexual response and an ointment therefor
EA199700213A1 (ru) Крем на водной основе для локального применения, способ его приготовления, способ лечения эректильной дисфункции у мужчин, способ лечения аноргазма у женщин, способ лечения микроваскулярных заболеваний и способ лечения ран или хирургических рассечений
ATE233091T1 (de) Verwendung von histamine-2 agonisten zur behandlung sexueller funktionsstörungen
NO20021035D0 (no) Fremgangsmåter for anvendelse av rasktvirkende selektive serotonin gjenopptakningsinhibitorer for behandling av seksuelldysfunksjon
ITMI922331A1 (it) Uso di paratormone, suoi frammenti biologicamente attivi e peptidi correlati, per la preparazione di composizioni farmaceutiche utili nella prevenzione e terapia dell'aborto e del parto pretermine ed in generale per il trattamento della gestazione
ATE289293T1 (de) Substituierte aminoalkylamid-derivate als antagonisten des follikel-stimulierenden hormons
RU2002104498A (ru) Применение тозилхлорамидов для лечения заболеваний кожи, слизистой оболочки, органов и тканей
US20080213407A1 (en) Topical application of L-arginine and menthol to increase penis size
AR019694A1 (es) Metodo para el tratamiento o reduccion de la disfuncion sexual femenina.
ES2042818T3 (es) Agente terapeutico para la trombocitopenia.
ECSP992843A (es) Procedimiento para aminorar la disfuncion sexual femenina
RU94031913A (ru) Способ лечения хронического кандидозного вульвовагинита
RU2224562C2 (ru) Способ лечения хронического простатита
RU2188675C2 (ru) Способ лечения больных с аменореей центрального генеза
KR20010076961A (ko) 성기능장애 예방 및 치료용 약제
TH65931A3 (th) ยาสำหรับหญิงที่เสื่อมสมรรถภาพทางเพศและวิธีการใช้
RU2529812C2 (ru) Биологически активная композиция
محمد أكرم رنداوا et al. A Review of the Developmental, Structural, Biochemical, Pathophysiological and Pharmacological Similarities between Male and Female Genitals
MXPA02001219A (es) Composicion farmaceutica liquida para el tratamiento de enfermedades oseas.
RU95101168A (ru) Способ формирования желаемого пола зарождаемого ребенка
Korda et al. THE FEMALE PROSTATE AND FEMALE EJACULATION IS KNOWN SINCE THE 11TH CENTURY: 1096
TH65931A (th) ยาสำหรับหญิงที่เสื่อมสมรรถภาพทางเพศและวิธีการใช้

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)